Cover Image
市場調查報告書

血鐵沉著症:開發中產品分析

Hemochromatosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 361626
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
血鐵沉著症:開發中產品分析 Hemochromatosis - Pipeline Review, H2 2016
出版日期: 2016年11月30日 內容資訊: 英文 42 Pages
簡介

本報告提供血鐵沉著症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

血鐵沉著症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

血鐵沉著症:企業開發中的治療藥

血鐵沉著症:大學/機關研究中的治療藥

血鐵沉著症:開發中產品概況

血鐵沉著症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

血鐵沉著症:企業開發中的產品

血鐵沉著症:大學/機關研究中的產品

血鐵沉著症的治療藥開發企業

  • Acino International AG
  • Ionis Pharmaceuticals, Inc.
  • La Jolla Pharmaceutical Company
  • Protagonist Therapeutics Inc.

血鐵沉著症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

血鐵沉著症:最近的開發平台趨勢

血鐵沉著症:暫停中的計劃

血鐵沉著症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8752IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemochromatosis - Pipeline Review, H2 2016, provides an overview of the Hemochromatosis (Genetic Disorders) pipeline landscape.

Hemochromatosis is an iron disorder in which the body simply loads too much iron. Symptoms include joint pain, abdominal pain, fatigue, weakness, diabetes, liver failure and heart failure. Risk factors include family history, alcoholism, taking dietary supplements with iron or vitamin C and history of diabetes, heart disease, or liver disease.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemochromatosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 1, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.Hemochromatosis.

Hemochromatosis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hemochromatosis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hemochromatosis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hemochromatosis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hemochromatosis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hemochromatosis (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hemochromatosis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hemochromatosis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Hemochromatosis Overview 6
  • Therapeutics Development 7
  • Pipeline Products for Hemochromatosis - Overview 7
  • Pipeline Products for Hemochromatosis - Comparative Analysis 8
  • Hemochromatosis - Therapeutics under Development by Companies 9
  • Hemochromatosis - Therapeutics under Investigation by Universities/Institutes 10
  • Hemochromatosis - Pipeline Products Glance 11
  • Clinical Stage Products 11
  • Early Stage Products 12
  • Hemochromatosis - Products under Development by Companies 13
  • Hemochromatosis - Products under Investigation by Universities/Institutes 14
  • Hemochromatosis - Companies Involved in Therapeutics Development 15
  • Ionis Pharmaceuticals Inc 15
  • La Jolla Pharmaceutical Company 16
  • Protagonist Therapeutics Inc 17
  • Hemochromatosis - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Target 19
  • Assessment by Mechanism of Action 21
  • Assessment by Route of Administration 23
  • Assessment by Molecule Type 25
  • Drug Profiles 27
  • CN-128 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • IONISTMPRSS-6LRx - Drug Profile 28
  • Product Description 28
  • Mechanism Of Action 28
  • R&D Progress 28
  • LJPC-401 - Drug Profile 29
  • Product Description 29
  • Mechanism Of Action 29
  • R&D Progress 29
  • M-012 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • NSC-8679 - Drug Profile 33
  • Product Description 33
  • Mechanism Of Action 33
  • R&D Progress 33
  • PTG-300 - Drug Profile 34
  • Product Description 34
  • Mechanism Of Action 34
  • R&D Progress 34
  • Recombinant Protein for Iron Overload Disorders - Drug Profile 35
  • Product Description 35
  • Mechanism Of Action 35
  • R&D Progress 35
  • Hemochromatosis - Dormant Projects 36
  • Hemochromatosis - Product Development Milestones 37
  • Featured News & Press Releases 37
  • Sep 07, 2016: La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401 37
  • Jul 28, 2016: Protagonist Therapeutics Receives SBIR Funding for the Development of Injectable Hepcidin Mimetics for Treatment of Iron Overload Disorders 37
  • Feb 24, 2016: Merganser Biotech Initiates First Clinical Trial 38
  • Oct 19, 2015: La Jolla Pharmaceutical Doses First Patient in Phase 1 Clinical Trial of LJPC-401 in Patients at Risk of Iron Overload 38
  • Aug 11, 2015: La Jolla Pharmaceutical Company Announces FDA Acceptance of IND for LJPC-401 39
  • Nov 01, 2011: UCLA scientists design experimental treatment for iron-overload diseases 39
  • Appendix 41
  • Methodology 41
  • Coverage 41
  • Secondary Research 41
  • Primary Research 41
  • Expert Panel Validation 41
  • Contact Us 41
  • Disclaimer 42

List of Tables

  • Number of Products under Development for Hemochromatosis, H2 2016 7
  • Number of Products under Development for Hemochromatosis - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Number of Products under Investigation by Universities/Institutes, H2 2016 10
  • Comparative Analysis by Clinical Stage Development, H2 2016 11
  • Comparative Analysis by Early Stage Development, H2 2016 12
  • Products under Development by Companies, H2 2016 13
  • Products under Investigation by Universities/Institutes, H2 2016 14
  • Hemochromatosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2016 15
  • Hemochromatosis - Pipeline by La Jolla Pharmaceutical Company, H2 2016 16
  • Hemochromatosis - Pipeline by Protagonist Therapeutics Inc, H2 2016 17
  • Assessment by Monotherapy Products, H2 2016 18
  • Number of Products by Stage and Target, H2 2016 20
  • Number of Products by Stage and Mechanism of Action, H2 2016 22
  • Number of Products by Stage and Route of Administration, H2 2016 24
  • Number of Products by Stage and Molecule Type, H2 2016 26
  • Hemochromatosis - Dormant Projects, H2 2016 36

List of Figures

  • Number of Products under Development for Hemochromatosis, H2 2016 7
  • Number of Products under Development for Hemochromatosis - Comparative Analysis, H2 2016 8
  • Number of Products under Development by Companies, H2 2016 9
  • Comparative Analysis by Early Stage Products, H2 2016 12
  • Assessment by Monotherapy Products, H2 2016 18
  • Number of Products by Targets, H2 2016 19
  • Number of Products by Stage and Targets, H2 2016 19
  • Number of Products by Mechanism of Actions, H2 2016 21
  • Number of Products by Stage and Mechanism of Actions, H2 2016 21
  • Number of Products by Routes of Administration, H2 2016 23
  • Number of Products by Stage and Routes of Administration, H2 2016 23
  • Number of Products by Molecule Types, H2 2016 25
  • Number of Products by Stage and Molecule Types, H2 2016 25
Back to Top